The following are members of The Bladder Cancer Study Group: Faculty of Medicine, The University of Tokyo (Katsuki Kawabe, Yoshio Aso); Branch Hospital, The University of Tokyo (Tadao Kitamura); Institute of Clinical Medicine, The University of Tsukuba (Hideyuki Akaza, Kenkichi Koiso); Dokkyo University, School of Medicine (Toru Suzuki, Etsuji Takasaki); Jichi Medical School, School of Medicine (Akihiko Tokue); Nihon University, School of Medicine (Kiyoki Okada); Juntendo University, School of Medicine (Makoto Fujime); Showa University, School of Medicine (Hideki Yoshida); Yamanashi Medical College (Hideki Komatsu, Akira Ueno); Medical College of Hamamatsu (Kimio Fujita); National Cancer Center Hospital (Tadao Kakizoe); Japan Red Cross Medical Center Hospital (Hiroyuki Kojima); National Medical Center (Yoichi Kishi); Mitsui Memorial Hospital (Yoji Nishimura); Toranomon Hospital (Masao Yokoyama); Fraternity Memorial Hospital (Takeshi Kawamura); Bokuto Metropolitan Hospital (Noriharu Mikata); Saitama Central Hospital (Yasunori Ishii); Tokyo the Aged Medical Center (Koji Nakauchi); Musashino Red Cross Hospital (Hiroshi Nito); Komagome Metropolitan Hospital (Kenji Kinoshita); Toshima Metropolitan Hospital (Takeshi Murayama); Kameda General Hospital (Toru Hara); Koshigaya Municipal Hospital (Makoto Morozumi).
Bacillus calmette—Guérin treatment of existing papillary bladder cancer and carcinoma in situ of the bladder. Four-year results
Article first published online: 28 JUN 2006
Copyright © 1995 American Cancer Society
Volume 75, Issue 2, pages 552–559, 15 January 1995
How to Cite
Akaza, H., Hinotsu, S., Aso, Y., Kakizoe, T., Bladder Cancer BCG Study Group (1995), Bacillus calmette—Guérin treatment of existing papillary bladder cancer and carcinoma in situ of the bladder. Four-year results. Cancer, 75: 552–559. doi: 10.1002/1097-0142(19950115)75:2<552::AID-CNCR2820750219>3.0.CO;2-H
- Issue published online: 28 JUN 2006
- Article first published online: 28 JUN 2006
- Manuscript Accepted: 13 SEP 1994
- Manuscript Received: 14 JUN 1994
- bacillus Calmette-Guérin;
- superficial bladder cancer;
- carcinoma in situ of the bladder;
- intravesical instillation
Background. Intravesical instillation therapy of Bacillus Calmette-Guérin (BCG) has become a standard treatment for carcinoma in situ (CIS) of the urinary bladder. However, there have been few reports concerning the direct effect of BCG on existing tumors classified as Ta or T1. In the first stage of this clinical study, 157 patients were treated with BCG intravesical instillation (Tokyo 172 strain [BCG Co. Ltd., Tokyo, Japan]; 80 mg weekly for eight times) by our Study Group. The efficacy on existing tumors was a complete response (CR) rate of 84.4% and 66.4% and a partial response (PR) of 6.3% and 20.8% for 32 cases of CIS and 125 cases of Ta or T1 tumors, respectively.
Methods. In the second stage of this study, the authors investigated the outcome of the 138 patients who had achieved CR or PR in the first stage. One hundred twenty (87.0%) of the patients were followed fully. Of those patients, 52 were randomized to receive prophylactic (maintenance) therapy consisting of BCG of 40 mg monthly for 12 times (Group A), whereas 55 were randomized to an untreated control group (Group B). Thirteen other patients refused to be randomized and were followed without prophylactic instillation.
Results. The median follow-up period was 48 months for Group A and 42 months for Group B. In Groups A and B, the beneficial effect of the BCG therapeutic instillation persisted for a long time, and the 3-year nonrecurrence rate was 77.6% in Group A and 74.2% in Group B. Disease progression was observed rarely.
Conclusion. For patients in whom transurethral resection of tumors of the bladder (TUR-Bt) alone is unlikely to eliminate the tumor, intravesical BCG is potentially the treatment of choice. Cancer 1995;75:552-9.